LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

Search

Ligand Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

115.34 0.03

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

112.63

Max

116.51

Belangrijke statistieken

By Trading Economics

Inkomsten

-11M

-42M

Verkoop

2.5M

45M

K/W

Sectorgemiddelde

47.016

50.291

EPS

1.33

Winstmarge

-93.643

Werknemers

68

EBITDA

-11M

-41M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+27.03% upside

Dividenden

By Dow Jones

Volgende Winsten

5 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

201M

2.2B

Vorige openingsprijs

115.31

Vorige sluitingsprijs

115.34

Nieuwssentiment

By Acuity

39%

61%

128 / 380 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 jun 2025, 23:49 UTC

Winsten

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 jun 2025, 22:19 UTC

Acquisities, Fusies, Overnames

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 jun 2025, 21:30 UTC

Winsten

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 jun 2025, 21:07 UTC

Winsten

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 jun 2025, 23:49 UTC

Marktinformatie

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 jun 2025, 23:39 UTC

Marktinformatie

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 jun 2025, 23:34 UTC

Acquisities, Fusies, Overnames

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 jun 2025, 23:33 UTC

Acquisities, Fusies, Overnames

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 jun 2025, 23:32 UTC

Acquisities, Fusies, Overnames

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 jun 2025, 23:32 UTC

Acquisities, Fusies, Overnames

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 jun 2025, 23:31 UTC

Acquisities, Fusies, Overnames

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 jun 2025, 23:31 UTC

Acquisities, Fusies, Overnames

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 jun 2025, 23:30 UTC

Acquisities, Fusies, Overnames

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 jun 2025, 23:29 UTC

Acquisities, Fusies, Overnames

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 jun 2025, 23:19 UTC

Acquisities, Fusies, Overnames

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 jun 2025, 22:06 UTC

Winsten

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 jun 2025, 21:15 UTC

Winsten

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 jun 2025, 21:07 UTC

Acquisities, Fusies, Overnames

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 jun 2025, 21:07 UTC

Acquisities, Fusies, Overnames

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 jun 2025, 21:07 UTC

Acquisities, Fusies, Overnames

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 jun 2025, 21:07 UTC

Winsten

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 jun 2025, 21:06 UTC

Acquisities, Fusies, Overnames

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 jun 2025, 21:06 UTC

Acquisities, Fusies, Overnames

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 jun 2025, 21:06 UTC

Marktinformatie

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 jun 2025, 21:05 UTC

Acquisities, Fusies, Overnames

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 jun 2025, 21:05 UTC

Acquisities, Fusies, Overnames

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 jun 2025, 20:52 UTC

Winsten

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 jun 2025, 20:51 UTC

Winsten

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 jun 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

26 jun 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Ligand Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

27.03% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 147 USD  27.03%

Hoogste 157 USD

Laagste 135 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ligand Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technische score

By Trading Central

102.5 / 109.24Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Very Strong Bearish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

128 / 380 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.